Roger Song
Stock Analyst at Jefferies
(2.82)
# 1,883
Out of 4,981 analysts
51
Total ratings
39.02%
Success rate
1.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRML Tourmaline Bio | Downgrades: Hold | $64 → $48 | $47.61 | -0.23% | 3 | Sep 9, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $405.02 | +39.25% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.93 | +159.07% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $6.03 | +181.92% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $10.83 | +232.41% | 1 | Aug 15, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Hold | $3 → $1.5 | $1.55 | -2.91% | 1 | Aug 5, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $37.10 | +45.55% | 3 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Buy | $31 → $6 | $5.73 | +4.71% | 2 | Jul 22, 2025 | |
| CVAC CureVac | Downgrades: Hold | $7 → $5 | $5.34 | -6.37% | 1 | Jun 13, 2025 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $15 → $30 | $48.68 | -38.37% | 11 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.95 | +103.39% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.22 | +117.39% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $143.68 | +70.52% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $6.97 | +273.03% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $4.80 | +45.83% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.19 | +241.88% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $1.95 | +258.97% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $59.80 | +48.83% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $7.98 | +213.28% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $9.05 | +353.04% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $20.18 | +73.44% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $32.18 | +300.87% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $2.00 | +300.00% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $80.54 | +20.44% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $24.81 | +343.37% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $3.64 | +861.54% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.13 | +696.46% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $5.83 | +37.22% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $0.88 | +2,294.80% | 1 | Sep 2, 2020 |
Tourmaline Bio
Sep 9, 2025
Downgrades: Hold
Price Target: $64 → $48
Current: $47.61
Upside: -0.23%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $405.02
Upside: +39.25%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.93
Upside: +159.07%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $6.03
Upside: +181.92%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $10.83
Upside: +232.41%
LAVA Therapeutics
Aug 5, 2025
Downgrades: Hold
Price Target: $3 → $1.5
Current: $1.55
Upside: -2.91%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $37.10
Upside: +45.55%
Replimune Group
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $5.73
Upside: +4.71%
CureVac
Jun 13, 2025
Downgrades: Hold
Price Target: $7 → $5
Current: $5.34
Upside: -6.37%
Nektar Therapeutics
Apr 11, 2025
Upgrades: Buy
Price Target: $15 → $30
Current: $48.68
Upside: -38.37%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $2.95
Upside: +103.39%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.22
Upside: +117.39%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $143.68
Upside: +70.52%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $6.97
Upside: +273.03%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $4.80
Upside: +45.83%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.19
Upside: +241.88%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $1.95
Upside: +258.97%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $59.80
Upside: +48.83%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $7.98
Upside: +213.28%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $9.05
Upside: +353.04%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $20.18
Upside: +73.44%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $32.18
Upside: +300.87%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $2.00
Upside: +300.00%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $80.54
Upside: +20.44%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $24.81
Upside: +343.37%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $3.64
Upside: +861.54%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $1.13
Upside: +696.46%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $5.83
Upside: +37.22%
Sep 2, 2020
Initiates: Buy
Price Target: $21
Current: $0.88
Upside: +2,294.80%